European Medicines Agency

Doc. Ref. EMEA/409573/2008
P/82/2008

EUROPEAN MEDICINES AGENCY DECISION

of 01 October 2008

on the application for agreement of a Paediatric Investigation Plan for Bevacizumab, (Avastin) EMEA-000056-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 01 October 2008

on the application for agreement of a Paediatric Investigation Plan for Bevacizumab, (Avastin) EMEA-000056-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Roche Registration Ltd on 20 September 2007 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation and a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 September 2008, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency, following a re-examination procedure of the Paediatric Committee's opinion according to Article 25(3) of Regulation (EC) No 1901/2006 as amended, has given a positive opinion,

(2) It is therefore appropriate to adopt a Decision following the Paediatric Committee's opinion on the Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a waiver.

(4) It is therefore appropriate to adopt a Decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for bevacizumab (Avastin), concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for bevacizumab (Avastin), concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A deferral for bevacizumab (Avastin), concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Roche Registration Ltd, 6 Falcon Way, Shire Park, AL7 1TW Welwyn Garden City.

Done at London, 01 October 2008

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

EMEA/PDCO/344163/2008
EMEA-000056-PIP01-07

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON A REQUEST FOR AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN FOR (AFTER RE-EXAMINATION)

Scope of the application

Active substance:
Bevacizumab

Invented name:
Avastin

Condition(s):
Rhabdomyosarcoma
Non-rhabdomyosarcoma soft tissue sarcoma

Pharmaceutical form(s):
Concentrate for solution for infusion

Route(s) of administration:
Intravenous use

Name/corporate name of the PIP applicant:
Roche Registration Ltd

Information about the authorised medicinal product:
See Annex II

Basis for opinion

Pursuant to Article 16.1 of Regulation (EC) No 1901/2006 as amended, Roche Registration Ltd submitted for agreement to the EMEA on 20 September 2007 a paediatric investigation plan for the above mentioned medicinal product.

An Opinion was adopted by the Paediatric Committee on 04 July 2008.

On 07 August 2008 Roche Registration Ltd submitted to the EMEA a written request, including detailed grounds for re-examination of the Opinion.

The re-examination procedure started on 27 August 2008.

A meeting with the Paediatric Committee took place on 17 September 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Final Opinion

1. The Paediatric Committee, having assessed the detailed grounds for the re-examination, in accordance with Article 25(3) of Regulation (EC) No 1901/2006 as amended, revises its opinion and recommends, as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended,
- to grant a deferral in accordance with Article 21 of Regulation (EC) No 1901/2006 as amended, and
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended and concluded in accordance with Article 11(1)(a) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Icelandic and Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix(ces).

London, 19 September 2008

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

– Rhabdomyosarcoma
– Non-rhabdomyosarcoma soft tissue sarcoma

B. WAIVER(S)

- **Condition**

– Rhabdomyosarcoma
– Non-rhabdomyosarcoma soft tissue sarcoma

- **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

The waiver applies to:
– Preterm newborn infants, term newborn infants (from birth to less than 28 days) and infants (from 28 days to less than 6 months) for the concentrate for solution for infusion for intravenous use on the grounds that the specific medicinal product is likely to be unsafe.

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

– Rhabdomyosarcoma
– Non-rhabdomyosarcoma soft tissue sarcoma

- **Proposed PIP indication**

Treatment of newly-diagnosed metastatic rhabdomyosarcoma or newly-diagnosed metastatic non-rhabdomyosarcoma soft tissue sarcoma

- **Subset(s) of the paediatric population concerned by the paediatric development**

Children aged 6 months to less than 18 years

- **Formulation(s)**

Concentrate for solution for infusion for intravenous use

- **Studies**

Area	Subarea	Number of studies	Description
Clinical	Pharmacokinetics, safety and efficacy	1	Randomised, open-label, multi-centre, comparative pharmacokinetic, safety and efficacy study of bevacizumab as add-on to combination chemotherapy

Need for paediatric measures in a EU-Risk Management Plan: Yes
Date of completion of the paediatric investigation plan: Not later than September 2014
A deferral has been granted: Yes

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU-Number	Invented name	Strength	Pharmaceutical Form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/04/300/001	Avastin	25 mg/ml	Concentrate for solution for infusion	Intravenous use	Vial	100 mg/4 ml (25 mg/ml)	1 vial
EU/1/04/300/002	Avastin	25 mg/ml	Concentrate for solution for infusion	Intravenous use	Vial	400 mg/16 ml (25 mg/ml)	1 vial